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•	 The IASLC Lung Cancer 
Staging Project: The New 
Database to Inform the 
8th Edition of the TNM 
Classification of Lung 
Cancer
from 35 sources in 16 countries, particularly those 
contributed via the online electronic data capture system 
(n = 4667) contained all required elements for refinement 
analysis of the TNM descriptors. Europe is the leading 
contributor (n = 46,560), followed by Asia (n = 41,705); 
whereas North America (n = 4660) and Australia (n = 
1593) presented with less cases compared with previous 
databases. South America contributed for the first time (n 
= 190). Patients predominantly received surgery alone, 
and fewer patients received chemotherapy alone or in 
combination with radiotherapy as a result of no clinical 
trial data in the analysis. There was a 50% decline in 
patients with SCLC, whereas the number of patients with 
NSCLC remained stable. The analysis will be based on 
established objectives for the TNM components to further 
assess the prognostic significance of (1) tumor size and 
the different T descriptors; (2) tumor burden in hilar and 
mediastinal lymph nodes; and (3) number and location of 
metastases, and confirmation of revised M1a and M1b of 
the 7th edition of the classification. The findings of these 
analyses and recommendations for revision will inform 
the 8th edition of the TNM classification, to be available 
in 2016. (p. 1618)
IN THIS ISSUE
The 7th edition of the tumor, node, and metastasis (TNM) 
classification of lung cancer, developed as a result of retrospective 
database analyses of the International Association for the Study 
of Lung Cancer (IASLC) between 1990 and 2000, did not provide 
sufficient detailed data for all descriptors of the TNM components 
to be validated, despite the large number of lung cancer patients 
involved (n = 81,495). The need to address these limitations fueled 
the initiation of a second phase of the Lung Cancer Staging Project 
by the IASLC Staging and Prognostic Factors Committee. The new 
database included 77,156 evaluable lung cancer patients (70,967 
non–small-cell lung cancer [NSCLC] and 6189 small cell lung cancer 
[SCLC]) diagnosed between 1999 and 2010. The data, obtained 
•	 Crizotinib Effects 
on Creatinine and 
Noncreatinine-Based 
Measures of Glomerular 
Filtration Rate
acute and chronic effects on kidney function. They 
found that chronic creatinine changes reflect a decline 
in the true GFR. Acute effects were observed with a 
decline in creatinine-based measure of the GFR but 
no decline in noncreatinine-based measurements, and 
a decrease in the true GFR that seemed more notable 
with preexisting renal impairment. The findings indicate 
that crizotinib is associated with different effects on 
kidney function: it could interfere with creatinine-
based measurement but not affect the true GFR, or its 
prolonged exposure could result in a reduction in the 
true GFR measured by different approaches. The authors 
suggest that the use of a noncreatinine, for instance 
iothalamate, based measurement of kidney function 
should be considered in addition to creatinine-based 
assessment that show crizotinib-related changes before 
treatment modifications involving crizotinib and other 
renally excreted drugs. (p. 1634)
The authors sought to investigate the effects of crizotinib on the 
measurement of kidney function using creatinine and iothalamate-
based estimates of glomerular filtration rate (GFR), and whether 
creatinine-based measure of kidney function is accurate in patients 
treated with crizotinib. The analysis of two patients with anaplastic 
lymphoma kinase (ALK)-positive NSCLC, one with preexisting 
renal impairment, demonstrated that crizotinib is associated with 
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non-V600 mutations (p =0.007). Nineteen percent of 
early stage BRAF mutant cancers developed second 
primary lung cancer with KRAS mutations. In advanced 
cancers, a significantly better 3-year OS was observed 
in V600 mutant lung adenocarcinomas versus non-V600 
mutant ones (24% versus 0%; p < 0.001). Ten of the 20 
patients with advanced V600 mutant cancers received 
prior BRAF inhibitor treatment, and had favorable 
response (6% partial response, 30% stable disease, and 
10% progressive disease). Taken together, the findings 
demonstrated that BRAF mutations (V600 and non-
V600) are more predominant in smokers. Patients with 
advanced V600 mutant lung cancers have a prolonged 
survival versus non-V600 mutant cancers, and have 
benefited from BRAF targeted therapy. The authors 
suggested routine repeat biopsies and genetic testing 
for patients with early stage BRAF mutant cancers, who 
developed second primary KRAS mutant lung cancer. 
Nonetheless, larger studies are required to confirm the 
results. (p. 1669)
•	 Clinical Characteristics 
and Course of 63 Patients 
with BRAF Mutant Lung 
Cancers
Patients in this study were screened for BRAF mutations on 
codons V600, D594, and G460, with a parallel analysis of their 
characteristics and treatment outcomes to determine the clinical 
characteristics and course of patients with lung adenocarcinomas 
harboring BRAF mutations. Overall survival (OS) was 
compared with patients harboring KRAS and EGFR mutant lung 
adenocarcinomas with matching stage. The analysis identified 63 
patients diagnosed with BRAF mutant cancers (2009–2013), in 
which 36 had V600 and 27 had non-V600 mutations. Smokers 
accounted for 92% of these patients; those harboring V600 
mutations were more likely to be light/never smokers versus 
•	 Lungscape: Resected 
NSCLC Outcome by 
Clinical and Pathologic 
Parameters
This report describes the results of the Lungscape 
project, which was aimed to facilitate studies on the 
outcome of clinically, pathologically, and molecularly 
characterized resected NSCLC. Fully annotated tissue 
samples (stages I–III NSCLC) were available from 
a decentralized biobank, contributed by selected 
participating centers based on their number of patients, 
tissue microarray facility, and documented ethical 
approval. Selected patients would have comprehensive 
clinical data, radical resection between 2003 and 2009 
with sufficient follow-up, and formalin-fixed tissue with 
sufficient quantity and quality. Analysis of the 2449 
patients from 15 centers showed that the 5-year OS 
decreased with stage: 69.6% and 63.6% for stages IA 
and IB, 51.6% and 47.7% for stages IIA and IIB, and 
29.0% and 13.0% for stages IIIA and IIIB, respectively 
(p < 0.001). Median and 5-year relapse-free survival 
(RFS) of 52.8 months and 47.3%, respectively were 
observed. Distant relapse occurred in 44.4% of patients 
whereas local relapse in 26.0%; 16.9% had both. 
Multivariate analysis demonstrated that performance 
status and pathological stage were significantly 
associated with OS, RFS, and time-to-relapse. These 
findings contributed to the first large surgical series 
observation on RFS and time-to-relapse in addition 
to OS for NSCLC surgical outcomes, and significant 
clinical and pathological prognostic factors. (p. 1675)
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This report describes for the first time two cases of crizotinib 
hypersensitivity in patients with advanced ALK-positive NSCLC. 
The two patients (aged 77 and 45, women, never smokers) had to 
discontinue crizotinib treatment as a result of the hypersensitivity 
reaction and were treated with a 12-step oral desensitization 
clinical protocol. Briefly, the patients were given loratidine and 
cetirizine (10 mg) the night before and the morning of 
desensitization, and fexofenadine (180 mg) before the 
start of desensitization. Dilutions of crizotinib capsule 
content were made (0.05, 0.5, and 5 mg/ml) and given 
to patients in a total of 250 mg in 12 steps over 3 hours, 
starting at 0.0625 mg with a doubling of each subsequent 
dose until a final dose of 125 mg was reached. A 
15-minute interval between each step was used to 
monitor patients for signs of hypersensitivity reaction. 
Both patients tolerated this desensitization protocol well 
with no further symptoms or signs of a hypersensitivity 
reaction. Subsequently, they were able to safely resume 
crizotinib treatment at 250 mg twice daily. (p. 1726) 
•	 Successful Desensitization 
of Two Patients with 
ALK-Positive Lung Cancer 
and Hypersensitivity to 
Crizotinib
Image source: FDA
RESEARCH WATCH
•	 Prevalence and Clinical 
Outcomes for Patients 
with ALK-Positive 
Resected Stages I to III 
Adenocarcinoma: Results 
from the European Thoracic 
Oncology Platform 
Lungscape Project
adenocarcinomas revealed a 6.2% prevalence of ALK 
positivity using IHC and at least 2.2% using FISH. 
FISH demonstrated 100% specificity and 35.0% 
sensitivity, whereas IHC showed 81.3% sensitivity for 
2+/3+ patients, underscoring the importance of IHC 
positivity in influencing the precision for predicting 
FISH positivity. Both IHC and FISH ALK positivity 
were associated with improved OS, which would help 
guide management and the design of future ALK 
inhibitor-based adjuvant clinical trials. Taken together, 
this study highlighted the value of a virtual biobank in 
acquiring useful data for personalizing treatment and 
expediting diagnostic tools for routine clinical use.
Blackhall FH, Peters S, Bubendorf L, et al. 
Prevalence and clinical outcomes for patients with 
ALK-positive resected stage I to III adenocarcinoma: 
results from the European Thoracic Oncology Platform 
Lungscape project. J Clin Oncol 2014;32:2780–2787.
Blackhall et al. reported the findings of the Lungscape project 
aimed to determine the prevalence and prognosis of ALK-positive 
stages I to III resected lung adenocarcinoma in a European 
population. Tissue sections from 1281 patients from the European 
Thoracic Oncology Platform Lungscape iBiobank were tested for 
ALK status using immunohistochemistry (IHC) and fluorescent 
in situ hybridization (FISH), in 16 participating centers under the 
same protocol. Screening of this large cohort of resected lung 
•	 Adults with Exclusively 
Pulmonary Metastases 
from Ewing Sarcoma May 
Benefit from Whole-Lung 
Irradiation
3-year EFS (p = 0.003), and the 3-year OS (p = 0.009). 
Compared with smokers, non-smokers had better EFS 
(61% versus 11%; p = 0.04) and less acute toxicities 
(36% versus 73%; p = 0.11). The findings indicated that, 
with acceptable toxicity, WLI is associated with nearly 
half of adult ES patients with pulmonary metastases who 
were free from PR at 3 years of treatment. Improved 
survival outcomes at 3 years were observed in nonsmokers 
and those with lung-only metastases compared with 
smokers and extrapulmonary metastases. The authors 
suggested more aggressive approach for the group with 
extrapulmonary metastases and smoking status as a 
significant prognostic factor in treatment with WLI.
Casey DL, Alektiar KM, Gerber NK, Wolden SL. 
Whole lung irradiation for adults with pulmonary 
metastases from Ewing sarcoma. Int J Radiat Oncol 
Biol Phys 2014;89:1069–1075.
The investigators sought to evaluate the feasibility of whole-lung 
irradiation (WLI) in adult patients with lung-only metastases from 
Ewing sarcoma (ES). The study analyzed 26 patients with ES, treated 
with 12 to 15 Gy of WLI for lung metastases, and followed up for a 
median of 3.8 years. The median age was 23. The 3-year cumulative 
incidence of pulmonary relapse (PR) was 55%, event-free survival 
(EFS) was 38%, and OS was 45%. Better outcomes were observed 
in patients with exclusively pulmonary metastases versus those 
with extrapulmonary metastases, including 3-year PR (p = 0.01), 
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77.8%, respectively). The incorporation of the TP53-
Arg72Pro polymorphism, which correlates with 
responses to platinum-based doublet chemotherapy, 
into the prediction analysis only marginally improved 
the predictive power. These findings suggest the clinical 
value of this signature of three miRNAs in predicting 
response to platinum-based chemotherapy in this 
patient population. Future studies with larger sample 
size collected using a standard protocol, prospective 
analysis of primary, recurrent and inoperable advanced 
tumors, and the effects of this three miRNA signature on 
chemosensitivity are required to confirm the findings.
Saito M, Shiraishi K, Matsumoto K, et al. A 
Three-microRNA Signature Predicts Responses to 
Platinum-Based Doublet Chemotherapy in Patients 
with Lung Adenocarcinoma. Clin Cancer Res 2014; 
doi:10.1158/1078-0432.ccr-14–1096.
•	 A Three-MicroRNA 
Signature Predicts 
Responses to Platinum-
Based Doublet 
Chemotherapy in Patients 
with Lung Adenocarcinoma
To evaluate the predictive value of intro-tumor micro (mi)RNAs for 
responses to platinum-based doublet chemotherapy in patients with 
recurring lung adenocarcinoma, the authors collected surgically 
resected lung adenocarcinoma tissues from patients treated with 
the chemotherapy when the tumor recurred. Differential expression 
of miRNAs in chemotherapy responders versus nonresponders 
was assessed in 40 test cohort samples (40.0% responders) and 
63 validation cohort samples (28.6% responders). A signature 
of three miRNAs (miR-1290, miR-196b, and miR-135a*) was 
identified to predict response of these patients to chemotherapy 
with high accuracy in test and validation cohorts (82.5% and 
•	 Prevalence and Correlates 
of Smoking and Cessation-
Related Behavior 
Among Survivors of 10 
Cancers: Findings from a 
Nationwide Survey 9 Years 
After Diagnosis
and income, and greater alcohol consumption were 
associated with current smoking. A history of cancer 
related to smoking was correlated with quitting after 
diagnosis. About a third of current smokers intended to 
quit, which increased to 40% within a month. Survivors, 
who were married, older, and heavy smokers had lower 
odds of intending to quit. Overall, the analyses uncovered 
the fact that survivors still smoke long after initial 
diagnosis at high levels. The identification of smoking 
status and patterns, likelihood of quitting, and intentions 
to quit could help stratify survivors at risk for continued 
smoking and guide cessation efforts for survivors.
Westmaas JL, Alcaraz KI, Berg CJ, Stein KD. 
Prevalence and correlates of smoking and cessation-
related behavior among survivors of ten cancers: findings 
from a nationwide survey nine years after diagnosis. 
Cancer Epidemiol Biomarkers Prev 2014;23;1783–1792.
This nationwide, longitudinal, quality-of-life study was conducted 
in survivors of 10 cancers to investigate their smoking patterns 
approximately 9 years after diagnosis, and characteristics correlated 
with quitting and intentions to quit. Cross-sectional analyses 
demonstrated that 9.3% of all survivors were current smokers (last 30 
days), of which 17.2% had bladder cancer, 14.9% had lung cancer, 
and 11.6% had ovarian cancer. Daily smokers, accounted for 83% 
of current smokers and smoked a mean of 14.7 cigarettes per day, 
whereas nondaily smokers smoked an average of 5.7 cigarettes per 
day over a mean of 10.9 smoking days. Younger age, lower education 
government actions. Radio ads rated most positively on 
the Perceived Effectiveness measure among smokers 
and nonsmokers were two health harms-focused ads, 
Coughing Child followed by Suffering. TV ad rated most 
positively across most measures and all subgroups was 
Baby Alive with strong graphic. The results suggest that 
adaptation of graphic health-harm ads developed in other 
countries could be successful in African countries. This 
would allow focusing scarce resources for tobacco control 
on ads distribution instead of new material development.
Perl R, Murukutla N, Occleston J, et al. 
Responses to antismoking radio and television 
ads among adult smokers and non-smokers across 
Africa: message-testing results from Senegal, 
Nigeria and Kenya. Tob Control 2014; doi: 10.1136/
tobaccocontrol-2014–051682.
•	 Responses to Antismoking 
Radio and Television 
Advertisements Among 
Adult Smokers and 
Nonsmokers Across 
Africa: Message-Testing 
Results from Senegal, 
Nigeria, and Kenya
The authors sought to determine the feasibility of adapting existing 
tobacco control advertisements (ads) on television and radio from 
high-income countries for Africa. This first systematic study recruited 
1078 adults, aged 18 to 40 (men and women, smokers and non-
smokers) from Kenya, Nigeria, and Senegal, who were then stratified 
by smoking status, sex, age, and socioeconomic status. Five radio 
and five TV antitobacco ads were rated on perceived effectiveness, 
potential behaviour change, and antitobacco industry support for 
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NEWS IN BRIEF
•	 The Largest Cancer 
Genome Atlas Genomic 
Analysis Uncovered 
New Way of Cancer 
Classification
Investigators from the Cancer Genome Atlas reported 
in the journal Cell, the largest and most comprehensive 
tumor genetic analysis from more than 3500 tumors 
across 12 cancer types via five genomewide platforms 
and one proteomic platform. They found that cancers 
are more likely to be genetically similar based on 
the cell-of-origin of the cancer instead of its tissue-
of-origin. The analysis revealed that lung squamous, 
head and neck, and a proportion of bladder cancers 
converged into one subtype with TP53 mutations, TP63 
amplifications, and increased levels of immune and 
proliferation pathway genes. Bladder cancers diverged 
into three pan-cancer subtypes. This new approach 
of classifying cancers is accounted for a change in 
classification of one in 10 cancers analyzed, potentially 
changing treatments for 10% of patients. This would 
also shift drug development to targeting broader 
groups of cancers with similar genomic. These findings 
represent a rich resource for data-mining and future 
discovery of novel cancer therapeutic interventions.
Image source: Maggie Bartlett|National Human 
Genome Research Institute
•	 Different Lung Cancer 
Rates with Different 
Subtype, Sex, Race/
Ethnicity, and Age
On the basis of information from the Surveillance, 
Epidemiology, and End Results program, Lewis et al. 
assessed overall lung cancer incidence and the trends by 
histology and demographic groups in the United States 
from 1977 to 2010 (whites and blacks) and from 1992 
to 2010 (white non-Hispanics, Asian/Pacific Islanders, 
and white Hispanics). Published in Cancer, their report 
showed an overall declining rate of lung cancer and 
revealed that the trends vary by sex, histologic type, 
racial/ethnic group, and age. Rates of squamous and 
small cell carcinoma have declined since the 1990s 
(62–53 per 100,000 person-years), less rapidly among 
women than men. Also declined was rate for unspecified 
lung cancer. Rates of adenocarcinoma decreased among 
menthrough 2005 but rose rapidly thereafter in all 
demographic groups. Young women had higher rates 
for adenocarcinoma than men in all groups. The authors 
concluded that the changes in lung cancer rates reflect 
historical cigarette smoking rates, duration, cessation, 
cigarette composition, and exposure to carcinogens. 
They also underscore the importance of monitoring 
these trends because diagnosis and treatment are based 
on specific characteristics of the cancer, for instance the 
detection of EGFR mutation and ALK rearrangements 
in adenocarcinomas that have influenced recent type-
specific trends.
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The collaboration between the NCI, all NCI-supported 
National Clinical Trials Network groups, the Alliance 
for Clinical Trials in Oncology, and the ECOG-
ACRIN Cancer Research Group has fueled the launch 
of the Adjuvant Lung Cancer Enrichment Marker 
Identification and Sequencing Trials (ALCHEMIST). 
The aim of the trials is to efficiently screen large number 
of patients to identify those with early-stage lung cancer 
harboring EGFR mutation or ALK rearrangement, and 
match them to EGFR or ALK inhibitors to evaluate 
their potential in tackling recurrence and prolonging 
survival for this patient population. About 6000 to 8000 
individuals will be screened across the United States 
over 5 to 6 years, with about 800 patients expected to 
be enrolled in the treatment trials. Surgically resected 
tissues will be tested for EGFR mutation and ALK 
rearrangement. Patients with tumors positive for the 
genetic alterations will be assigned to randomized and 
placebo-controlled trials with adjuvant erlotinib (EGFR) 
or crizotinib (ALK) therapies. The findings from 
ALCHEMIST would shed lights on additional targeted 
therapies for early stage lung cancer, the prevalence and 
natural history of the genomic alterations in this disease, 
and the genetic changes related to tumor recurrence.
•	 ALCHEMIST Launched by 
NIH for Early-Stage Lung 
Cancer Patients
Image source: NIH
Institute, eventually becoming Deputy Director before 
his appointment as U.S. Surgeon General. Steinfield 
was the first Surgeon General to raise concerns about 
the potential adverse effect of tobacco smoke on 
nonsmokers, which lead to a first formal review of the 
evidence on the dangers of second-hand smoke in the 
1972 Surgeon General’s report. Dr. Steinfeld also was 
an outspoken critic of marketing of tobacco toward 
women and called for more resolute health warnings 
on tobacco packaging.
Leading cancer research and tobacco control 
organizations have recognized his achievements, 
including the IASLC https://www.iaslc.org/articles/
jesse-leonard-steinfeld-md, the American Association 
for Cancer Research http://aacr.informz.net/z/ 
cjUucD9taT00MTk4NTEwJnA9MSZ1PTEwMDI 
xODg0NjMmbGk9MjQyMDE3NDI/index.html,  
and ASCO as both a former Surgeon General  
and last ASCO president. http://connection.asco.org/
Magazine/Article/ID/3974/ASCO-Mourns-Jesse-
L-Steinfeld-MD-Former-Surgeon-General-ASCO-
President.aspx.
•	 News from the IASLC 
Tobacco Control 
Committee: Recognition of 
a Tobacco Control Pioneer
August 5, 2014 saw the passing of Jesse Leonard Steinfeld, MD, 
a former U.S. surgeon general (1969–1973). He was graduated 
from the University of Pittsburgh and taught at the University 
of Southern California before moving to the Nation Cancer 
Image source: NIH
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•	 This Months’ E-Cig Update By following the link below (and logging in or 
registering to Medscape) one can watch an “e-cig” 
blog from an American physician who spent some time 
exploring the issue of e-cigs prompted by his patients’ 
use of e-cigarettes. He wondered if they really were “the 
healthy option” and goes through the history of e-cigs 
in some detail. The 8-minute video comments on the 
origin of e-cigarettes, the possible difference between 
“smoking” and “vaping”, the use of vehicle agents, 
and the cost difference compared with conventional 
cigarettes (usually less). In an updated comment, a 
reference is provided to the e-cig review in Circulation 
(Circulation 2014;129:1972–1986), highlighted in this 
column last month.
Available at: http://www.medscape.com/
viewarticle/801964
•	 A Tobacco-Free Generation
There are all sorts of ways to control tobacco use, or least to try. 
The tiny Australian state of Tasmania (population approximately 
500,000) is considering adopting a law first suggested in Singapore 
a few years ago that would prohibit the sale of tobacco products to 
anyone born after the year 2000. The proposed law was reported in 
The Mercury on August 24 (“Push on to ban those born after 2000 
from smoking”, see link below). In an attempt to prevent future 
generations from ever even starting to smoke, the state is waiting on 
a report into proposed legislation to ban smoking in those turning 
14 this year. The article claims endorsement from the children of 
Tasmania, and the pending report will have input from both primary 
and secondary school children. Which, if you read the comments 
below the online article, is more than one can expect from some of 
the adults.
A very large country, India (population > 1.2 
billion), is also considering a law that would prohibit 
the production of cigarettes across the country. 
This will add another layer of control to the ban on 
selling cigarettes to those younger than 18 and to the 
prohibition on smoking in public places (since 2008). 
The Supreme Court issued notices to this effect earlier 
this month after an application was made to the court 
by a film maker, Sunil Rajpal. According to the NDTV 
Web site, the Supreme Court notice to central and state 
governments, seeks a decision on such a ban.
Available at: http://www.themercury.com.au/news/ 
tasmania/push-on-to-ban-those-born-after-2000- 
from-smoking/story-fnj4f7k1-1227034504194
Available at: https://en-maktoob.news.yahoo.com/
sc-issues-notice-plea-ban-cigarettes-070425656.html
Available at: http://www.thestatesman.net/
news/71630-ban-smoking-sc-to-centre-and-states.html
Available at: http://www.ndtv.com/article/india/
supreme-court-issues-notice-to-centre-states-on-plea-to-
ban-smoking-576091
Available at: http://www.dnaindia.com/india/report-
supreme-court-issues-notice-to-centre-on-pil-seeking-
ban-on-smoking-products-2010764
